TNFRSF21 and multiple sclerosis: DR6 inhibition has shown therapeutic benefit in several models of neurodegeneration, including amyotrophic lateral sclerosis [6, 7], multiple sclerosis [32, 33], prion disease [8], and in vitro amyloid-beta toxicity [5].